883 related articles for article (PubMed ID: 32708317)
21. In situ expression of RANKL, RANK, osteoprotegerin and cytokines in osteoclasts of rat periodontal tissue.
Ogasawara T; Yoshimine Y; Kiyoshima T; Kobayashi I; Matsuo K; Akamine A; Sakai H
J Periodontal Res; 2004 Feb; 39(1):42-9. PubMed ID: 14687227
[TBL] [Abstract][Full Text] [Related]
22. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
Tanaka S
Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
[TBL] [Abstract][Full Text] [Related]
23. Iguratimod suppresses sclerostin and receptor activator of NF-κB ligand production via the extracellular signal-regulated kinase/early growth response protein 1/tumor necrosis factor alpha pathway in osteocytes and ameliorates disuse osteoporosis in mice.
Miura T; Etani Y; Noguchi T; Hirao M; Takami K; Goshima A; Kurihara T; Fukuda Y; Ochiai N; Kanamoto T; Nakata K; Okada S; Ebina K
Bone; 2024 Apr; 181():117026. PubMed ID: 38325651
[TBL] [Abstract][Full Text] [Related]
24. RANKL subcellular trafficking and regulatory mechanisms in osteocytes.
Honma M; Ikebuchi Y; Kariya Y; Hayashi M; Hayashi N; Aoki S; Suzuki H
J Bone Miner Res; 2013 Sep; 28(9):1936-49. PubMed ID: 23529793
[TBL] [Abstract][Full Text] [Related]
25. Promising bone-related therapeutic targets for rheumatoid arthritis.
Choi Y; Arron JR; Townsend MJ
Nat Rev Rheumatol; 2009 Oct; 5(10):543-8. PubMed ID: 19798028
[TBL] [Abstract][Full Text] [Related]
26. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands.
Horowitz MC; Xi Y; Wilson K; Kacena MA
Cytokine Growth Factor Rev; 2001 Mar; 12(1):9-18. PubMed ID: 11312114
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms involved in normal and pathological osteoclastogenesis.
Park-Min KH
Cell Mol Life Sci; 2018 Jul; 75(14):2519-2528. PubMed ID: 29670999
[TBL] [Abstract][Full Text] [Related]
28. Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice.
Weinstein RS; O'Brien CA; Almeida M; Zhao H; Roberson PK; Jilka RL; Manolagas SC
Endocrinology; 2011 Sep; 152(9):3323-31. PubMed ID: 21771887
[TBL] [Abstract][Full Text] [Related]
29. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
30. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
31. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
32. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis.
Kramer I; Halleux C; Keller H; Pegurri M; Gooi JH; Weber PB; Feng JQ; Bonewald LF; Kneissel M
Mol Cell Biol; 2010 Jun; 30(12):3071-85. PubMed ID: 20404086
[TBL] [Abstract][Full Text] [Related]
33. [Melatonin and bone status].
Ostrowska Z; Wołkowska-Pokrywa K; Kos-Kudła B; Swietochowska E; Marek B; Kajdaniuk D
Pol Merkur Lekarski; 2006 Oct; 21(124):389-93. PubMed ID: 17205785
[TBL] [Abstract][Full Text] [Related]
34. Osteocytes subjected to fluid flow inhibit osteoclast formation and bone resorption.
Tan SD; de Vries TJ; Kuijpers-Jagtman AM; Semeins CM; Everts V; Klein-Nulend J
Bone; 2007 Nov; 41(5):745-51. PubMed ID: 17855178
[TBL] [Abstract][Full Text] [Related]
35. The osteoclast, bone remodelling and treatment of metabolic bone disease.
Boyce BF; Rosenberg E; de Papp AE; Duong LT
Eur J Clin Invest; 2012 Dec; 42(12):1332-41. PubMed ID: 22998735
[TBL] [Abstract][Full Text] [Related]
36. Osteoclasts have multiple roles in bone in addition to bone resorption.
Boyce BF; Yao Z; Xing L
Crit Rev Eukaryot Gene Expr; 2009; 19(3):171-80. PubMed ID: 19883363
[TBL] [Abstract][Full Text] [Related]
37. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
38. Parathyroid hormone signaling in mature osteoblasts/osteocytes protects mice from age-related bone loss.
Uda Y; Saini V; Petty CA; Alshehri M; Shi C; Spatz JM; Santos R; Newell CM; Huang TY; Kochen A; Kim JW; Constantinou CK; Saito H; Held KD; Hesse E; Pajevic PD
Aging (Albany NY); 2021 Dec; 13(24):25607-25642. PubMed ID: 34968192
[TBL] [Abstract][Full Text] [Related]
39. Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss.
Kleyer A; Scholtysek C; Bottesch E; Hillienhof U; Beyer C; Distler JH; Tuckermann JP; Schett G; Krönke G
J Bone Miner Res; 2012 Dec; 27(12):2442-51. PubMed ID: 22806960
[TBL] [Abstract][Full Text] [Related]
40. Matrix-embedded cells control osteoclast formation.
Xiong J; Onal M; Jilka RL; Weinstein RS; Manolagas SC; O'Brien CA
Nat Med; 2011 Sep; 17(10):1235-41. PubMed ID: 21909103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
